The Food and Drug Administration (FDA) has approved AstraZeneca’s Bydureon Pen, a pre-filled, single-use, pen-style delivery system for the injectable type 2 diabetes drug Bydureon. Bydureon, also known as exenatide, was approved by the FDA in 2012. It is the first and only once-weekly medicine to treat type 2 diabetes in adults. The Bydureon Pen eliminates the need for the patient to transfer the medication between a vial and syringe during the self-injection process. The pen contains the same formulation and dose as the original Bydureon single-dose tray, providing the same continuous release of exenatide. Bydureon is in a class ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.